Ground News

News from bariatricnews.net

See all of bariatricnews.net’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 100 headlines written by bariatricnews.net during the past 3 months.

The Ground News media bias check for bariatricnews.net is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

Is bariatricnews.net credible or reliable? Our Factuality score answers both of those questions. When it comes to bariatricnews.net, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about bariatricnews.net

Where is bariatricnews.net located?bariatricnews.net's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top bariatricnews.net News

Health · United Kingdom

Weight loss and diabetes jabs linked to potentially fatal side effect

59% Center coverage: 63 sources

See the Story

Pharma · United States

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

64% Center coverage: 40 sources

See the Story

Novo Nordisk · Denmark

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

76% Center coverage: 33 sources

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story

Weight-Loss Injections Are Dominating the Market: Where Will GLP-1 Pills Fit in? | News Channel 3-12

73% Center coverage: 15 sources

Weight-loss injections are dominating the market: Where will GLP-1 pills fit in? Glucagon-like peptide-1 (GLP-1) medications have emerged as powerful tools for weight loss. So far, injectable options like Wegovy (semaglutide) and Zepbound (tirzepatide) have led the way. And their benefits go beyond weight loss alone — as they’ve shown to improve heart health, kidney health, and even sleep apnea. But injectable medications aren’t right for everyo…Jenny Mollen See the Story

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

86% Center coverage: 7 sources

Findings also show improved persistence with high-potency, obesity-approved GLP-1 productsObesity · West Virginia See the Story

International expert consensus statements on surgery for T2DM

An International panel of experts has published 43 statements on the nature, terminology and mechanisms of action of metabolic and bariatric surgery (MBS), which the panel believes will guide clinicians on various aspects of MBS for T2DM, also grades the quality of the available evidence for each of the proposed statements.The panel embarked on a Delphi consensus-building exercise to propose an evidence-based expert consensus covering various as…Read Article

Qaelon Medical establishes Data Advisory Board to detect, prevent and predict surgical leaks

Qaelon Medical has announced the formation of its Data Advisory Board (DAB) dedicated exclusively to data-driven detection, prevention and prediction of surgical leaks. This multidisciplinary board will be comprised of leading surgeons, data scientists, health economists, and digital health experts that will define Qaelon's data strategy with initial focus on development of a comprehensive open-source dataset on surgical leaks and gastrointestin…Read Article

New drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass

A new potential drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass, according to a new study by researchers from Karolinska Institutet and Stockholm University.The new drug, which is taken in tablet form, has a completely different mechanism of action than the well-known GLP-1-based drugs, administered via injections. GLP-1 drugs affect hunger via signals between the gut and the brain, but ofte…Sweden · Sweden See the Story

Nitinotes to initiate US trial of the EndoZip System for endoscopic sleeve gastroplasty

Nitinotes has received approval from the FDA to initiate a pivotal clinical trial of the EndoZip System for endoscopic sleeve gastroplasty (ESG) under an Investigational Device Exemption (IDE). This prospective, multi-centre, randomised controlled trial will evaluate the safety and efficacy of the EndoZip System for the treatment of obesity. Up to 184 patients will be enrolled across as many as ten US clinical sites, with additional internationa…United States · United States Read Article

Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome

Researchers from the George Washington University have uncovered evidence in an animal study that shows setmelanotide, an FDA-approved medication for a rare genetic obesity disorder, may offer a pathway for treating a life-threatening form of sleep-disordered breathing called Obesity Hypoventilation Syndrome.Obesity Hypoventilation Syndrome which affects an estimated five to 10 million Americans commonly coexists with obstructive sleep apnoea. W…United States · United States Read Article

Weighted Vests Don't Protect Bone Health In Dieting Seniors, Trial Says

60% Center coverage: 10 sources

Key TakeawaysAugusta, Georgia · Augusta See the Story

News from bariatricnews.net

News from bariatricnews.net

Information about bariatricnews.net

Media Bias Ratings

Factuality

Ownership

Top bariatricnews.net News

Weight loss and diabetes jabs linked to potentially fatal side effect

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

Weight-Loss Injections Are Dominating the Market: Where Will GLP-1 Pills Fit in? | News Channel 3-12

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

International expert consensus statements on surgery for T2DM

Qaelon Medical establishes Data Advisory Board to detect, prevent and predict surgical leaks

New drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass

Nitinotes to initiate US trial of the EndoZip System for endoscopic sleeve gastroplasty

Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome

Weighted Vests Don't Protect Bone Health In Dieting Seniors, Trial Says

Similar News Topics

Topics Most Covered by bariatricnews.net

Sources Covering Similar Topics

Breaking News Topics Related to bariatricnews.net